Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

  • Nogales, Vanesa
  • Reinhold, William C.
  • Varma, Sudhir
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Moutinho, Catia|||0000-0003-3885-0847
  • Moran, S.|||0000-0003-4192-8983
  • Heyn, Holger|||0000-0002-3276-1889
  • Sebio, Ana|||0000-0003-3333-2370
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Pommier, Yves
  • Esteller, M.|||0000-0003-4490-6093
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized as a factor conferring distinct tumoral drug sensitivity, so we have used a comprehensive DNA methylation microarray platform to interrogate the widely characterized NCI60 panel of human cancer cell lines with respect to CpG methylation status and cisplatin/carboplatin sensitivity. Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds. We have also experimentally validated these findings in vitro. In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for the observed chemoresistance effect. Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia

  • Anadón, C.
  • van Tetering, G.
  • Ferreira, H. J.
  • Moutinho, Catia|||0000-0003-3885-0847
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Soler, Marta|||0000-0002-6656-957X
  • Heyn, Holger|||0000-0002-3276-1889
  • Moran, S.|||0000-0003-4192-8983
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Setien, F.
  • Vidal, A.
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Guil, Sonia|||0000-0002-2257-3331
  • Esteller, M.|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime|||0000-0003-1013-4128
  • Ortiz-Barahona, V.
  • de Moura, M. C.
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Soler, Marta|||0000-0002-6656-957X
  • Nachmani, D.
  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Schumann, U.
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Moran, S.|||0000-0003-4192-8983
  • Guil, Sonia|||0000-0002-2257-3331
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Piñeyro, David|||0000-0001-5633-3339
  • Perez-Salvia, Montserrat
  • Rosselló-Tortella, M.
  • Piqué, Laia
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Vidal, August|||0000-0001-5727-2099
  • Martínez-Iniesta, M.
  • Martín-Tejera, J. F.
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.|||0000-0002-8271-612X
  • La Madrid, A. M.
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Santa-Maria, V.
  • Mora, J.
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fraga, M. F.
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Vidal, Noemí|||0000-0002-2852-6667
  • Martinez, Fina|||0000-0002-0940-1025
  • Tortosa, Avelina|||0000-0002-9080-2976
  • Carrato, Cristina|||0000-0002-1953-8287
  • Balañá, Carmen|||0000-0003-0771-0390
  • Boudreau, M. W.
  • Hergenrother, P. J.
  • Kötter, P.
  • Entian, K. D.
  • Hench, Jürgen
  • Frank, Stephan|||0000-0001-6165-0187
  • Mansouri, S.
  • Zadeh, G.
  • Dans, P. D.
  • Orozco López, Modesto|||0000-0002-8608-3278
  • Thomas, Gareth J.
  • Blanco, Sandra
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Preiss, T.
  • Pandolfi, P. P.
  • Esteller, M.|||0000-0003-4490-6093
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer

  • Piqué, Laia
  • Martinez de Paz, A.
  • Piñeyro, David|||0000-0001-5633-3339
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Setien, F.
  • Gómez-Miragaya, Jorge|||0000-0003-1801-4681
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Sigurdsson, S.|||0000-0002-5284-0058
  • Jonasson, J. G.
  • Villanueva, Alberto|||0000-0001-5164-0006
  • Vidal, A.
  • Davalos, Veronica|||0000-0003-4077-5137
  • Esteller, M.|||0000-0003-4490-6093
Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma, implications for biomarker-driven clinical trials

  • Montal, Robert
  • Andreu-Oller, Carmen|||0000-0001-7405-9134
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Esteban-Fabró, Roger
  • Moran, S.|||0000-0003-4192-8983
  • Montironi, Carla|||0000-0002-1453-2193
  • Moeini, Agrin
  • Pinyol, Roser|||0000-0002-0288-6314
  • Peix, Judit
  • Cabellos, Laia
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Sia, Daniela|||0000-0002-9000-611X
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
  • Esteller, M.|||0000-0003-4490-6093
  • Llovet, Josep M.|||0000-0003-0547-2667
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration.